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Abstract
Objectives:	The	aim	of	Working	Group	1	was	to	address	the	influence	of	different	
local	 (implant	 length,	 diameter,	 and	 design)	 and	 systemic	 (medications)	 factors	 on	
clinical,	 radiographic,	and	patient‐	reported	outcomes	 in	 implant	dentistry.	Focused	




Consensus	 Conference	 and	were	 discussed	 among	 the	 participants	 of	 Group	 1.	
Consensus	statements,	clinical	recommendations,	and	recommendations	for	future	
research	were	based	on	structured	group	discussions	until	consensus	was	reached	
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1  | INTRODUC TION








the	 data	 and	 the	 meta‐	analysis	 of	 the	 individual,	 systematic	 re‐
views	and	basis	on	thorough	discussions	among	the	participants	of	
Group	1	and	among	the	entire	plenum	of	the	conference	consen‐
sus	 statements	 and	 clinical	 recommendations	were	 carefully	 for‐















Vivianne	 Chappuis,	 Gustavo	 Avila‐Ortiz,	 Mauricio	 Araújo,	
Alberto	Monje
2  | SURVIVAL R ATES OF SHORT DENTAL 
IMPL ANTS (≤6 MM) COMPARED WITH 
IMPL ANTS LONGER THAN 6 MM IN 
POSTERIOR JAW ARE A S: A META- ANALYSIS
2.1 | Preamble
Short	 implants	have	been	proposed	as	an	alternative	to	eliminate	or	
reduce	 the	 need	 for	 vertical	 bone	 augmentation	 procedures,	which	
are	 often	 associated	 with	 additional	 costs,	 longer	 treatment	 time,	
increased	postoperative	morbidity,	and	greater	risk	for	complications.	
However,	the	long‐	term	efficacy	of	short	dental	implants	has	been	a	







complicated	by	 the	 fact	 that	authors	have	defined	“short	dental	 im‐
plants”	differently.	Some	have	considered	<10	mm	as	short,	whereas	



















Sufficient	 data	were	 available	 to	 perform	 a	meta‐	analysis	 of	
the	 primary	 outcome	 (implant	 survival).	 Only	 descriptive	 analy‐
ses	were	possible	for	the	secondary	outcomes	radiographic	bone	





of	 both	 types	 of	 implants.	 The	other	 seven	 studies	 compared	 the	
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2.2 | Consensus statements
2.2.1 | Consensus statement 1


















Short	 and	 longer	 implants	 present	 similar	 amounts	 of	 radio‐











short	 implants	 (mean:	6.8%;	 range:	0–26%).1	 In	 the	 longer	 implant	


















2.3.2 | Should longer implants be the first choice?
The	selection	of	 the	 length	of	an	 implant	depends	on	site‐	specific	
local	 anatomical	 and	 patient	 conditions.	 When	 sufficient	 bone	
height	exists,	 implants	 longer	 than	6	mm	are	preferred	when	they	
can	be	placed	without	increasing	surgical	risk.
2.3.3 | Can short implants be immediately loaded?
The	 loading	 times	 for	 short	 implants	 reported	 in	 the	 litera‐
ture	 ranged	 from	 6	weeks	 to	 6	months.	 At	 the	 present	 time,	 no	
evidence‐	based	 recommendation	 can	 be	 made	 for	 immediate	
loading.








2.3.5 | What are the occlusal considerations for 
restorations on short implants?
Although	the	reviewed	literature	does	not	give	specific	recommen‐
dations	 regarding	 occlusion,	 a	 greater	 risk	 of	 occlusal	 overload	 of	
short	 implants	 has	 to	 be	 considered.	Caution	 is	 especially	 advised	
when	 indicating	 short	 implants	 in	 patients	 presenting	 with	 single	
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2.4 | Recommendations for future research
•	 Prospective	 long‐term	 clinical	 studies	 on	 the	 performance	 of	
short	implants	(>5	years)
•	 Randomized	 clinical	 trials	 comparing	 short	 and	 longer	 im‐
plants	 in	 intact	 bone	 sites	 without	 the	 need	 for	 vertical	 bone	
augmentation.
•	 RCTs	 or	 long‐term	 controlled	 clinical	 studies	 on	 the	 effect	 of	
splinting
•	 Studies	on	optimal	implant	design	for	short	implants
3  | NARROW DIAMETER IMPL ANTS: A 



























erable	 variation,	with	 a	 high	 risk	 of	 bias.	 It	 should	 be	 noted	 that	









































There	 is	 insufficient	 evidence	 on	 the	 success	 rates	 for	 all	 NDIs.	




























3.3.3 | Should NDI be splinted?
Given	 the	 reduced	 implant	 strength	 and	 bone	 contact	 offered	 by	
NDI,	 it	may	be	advisable	to	use	splinted	restorations	based	on	the	
individual	clinical	situation.

















3.4 | Recommendations for future research
•	 Future	studies	should	compare	the	success	and	patient‐reported	
outcome	measures	 between	NDI	without	 augmentation	 proce‐
dure	and	SDI	with	an	augmentation	procedure.
•	 Future	 studies	 should	 document	 long‐term	 results	 of	 potential	
technical	and	biological	complications
•	 Future	 studies	 should	 compare	 new	 materials	 and	 implant	
designs.
•	 Future	 studies	 should	 investigate	 the	 aesthetic	 outcome	 of	
NDI.
4  | SYSTEMATIC RE VIE W OF CLINIC AL 
AND PATIENT-  REPORTED OUTCOMES 
FOLLOWING OR AL REHABILITATION ON 
DENTAL IMPL ANTS WITH A TAPERED 




systematic	 review,	a	 tapered	 implant	 is	 recognized	as	a	 cylindrical	
implant	where	the	endosseous	part	narrows	in	diameter	toward	the	




patients	 with	 dental	 implant	 restorations,	 do	 tapered	 compared	
to	 non‐tapered	 implants	 demonstrate	 similar	 clinical	 and	 patient‐	
reported	outcomes?
Twenty‐	nine	 articles	 were	 identified	 of	 which	 three	 RCTs	 re‐
ported	outcomes	at	3	years.	The	three	RCTs	described	the	results	of	
245	patients	with	388	implants	at	three	years	and	reported	clinically	
insignificant	 differences.	 The	 three	 RCTs	 each	 reported	 different	
clinical	outcomes	and	the	data	were	not	comparable.	None	reported	




The	 evidence	 shows	 that	 both	 tapered	 and	 non‐tapered	 implants	





pared	 with	 non‐tapered	 implants	 demonstrate	 similar	 clinical	 and	




4.3.1 | Is there a recommendation for any specific 
implant design with regard to taper?
Based	 on	 Consensus	 statements	 1	 and	 2,	 both	 tapered	 and	
non‐tapered	 implants	 can	 be	 used	 according	 to	 the	 operator’s	
preference.
4.3.2 | Are there particular clinical situations in which 





must	 include	 a	 comprehensive	 diagnosis	 of	 the	 patient’s	 jawbone	
anatomy,	bone	quality	and	quantity,	and	osteotomy	protocol.
4.3.3 | Is utilizing a tapered implant an effective 
strategy to increase insertion torque?
In	 situations	where	 increased	 insertion	 torque	 is	 desired,	 tapered	
implants	may	be	considered.	The	shape	of	the	dental	implant	is	only	
one	contributing	 factor	 to	achieve	high	 insertion	torque;	however,	
the	 clinical	 significance	 of	 implant	 shape	 on	 long‐	term	 results	 is	
unclear.









•	 Establish	 whether	 insertion	 torque	 and	 resonance	 frequency	
analysis	are	valid	indicators	of	the	risk	of	micromotion	as	a	func‐
tion	of	the	implant	design.
5  | MEDIC ATION- REL ATED DENTAL 




tancy	of	 life	 is	 increasing	worldwide.	 These	demographic	 changes	
have	been	associated	with	an	increase	in	the	intake	of	medications	
for	 the	 treatment	of	highly	prevalent	medical	 conditions.	Some	of	
these	medications	may	influence	tissue	metabolism	and,	therefore,	















A	 total	of	 five	different	categories	of	medications	were	 identi‐
fied	 upon	 completion	 of	 the	 systematic	 search:	 nonsteroidal	 anti‐	
inflammatory	 medication	 (NSAIDs),	 antihypertensive	 medication	
(AHTNs),	 selective	 serotonin	 reuptake	 inhibitors	 (SSRIs),	 proton	




for	 any	 of	 the	 secondary	 outcomes.	 Limitation	 of	 this	 systematic	
F IGURE  1 Different	types	of	configurations	and	geometrie	for	tapered	implants	available	on	the	dental	market
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review	is	related	to	differences	in	study	design	and	medication	reg‐
imens,	in	addition	to	confounding	factors,	such	as	comorbidity	and	
polypharmacy	 among	others	 reported	 in	 the	 literature.	Therefore,	
the	 findings	 of	 this	 systematic	 review	 should	 be	 interpreted	with	
caution.
5.2 | Consensus statements





5.2.2 | Consensus statement 2: nonsteroidal anti‐ 
inflammatory drugs (NSAIDs)


















i.e.,	 Beta‐	blockers,	 Thiazide	 diuretics,	 Angiotensin‐	converting	
enzyme	inhibitors,	Angiotensin	II	receptor	blockers	and	others.





rospective	 cohort	 studies	 including	 a	 total	 of	 790	 patients,	which	




i.e.,	 Citalopram,	 Dapoxetine,	 Escitalopram,	 Fluoxetine,	
Fluvoxamine,	 Indalpine,	 Paroxetine,	 Sertraline,	 Venlafaxine	 and	
Zimeline	and	others.
5.2.5 | Consensus statement 5: proton pump 
inhibitors (PPIs)










5.2.6 | Consensus statement 6: bisphosphonates 
(BPs) related to osteoporosis
The	intake	of	BPs	related	to	the	treatment	of	osteoporosis	was	not	
associated	with	an	increased	implant	failure	rate.
This	 statement	 is	 based	 on	 the	 quantitative	 analysis	 of	 six	
cohort	 studies	 (i.e.,	 five	 retrospective	on	oral	BPs	and	one	pro‐
spective	 using	 intravenous	 BPs	 including	 a	 total	 of	 1,239	 pa‐
tients),	 which	 suggested	 that	 implant	 failure	 rate	was	 higher	 in	
subjects	 taking	 BPs	 as	 compared	 to	 a	 control	 population	 (aver‐
age	 difference:	 −0.13%,	 C.I.	 [95%]	=	−0.3	 to	 0.05,	 between	 12	
and	66	months	of	 follow‐	up).	Caution	should	be	 taken	when	 in‐
terpreting	 these	 data	 due	 to	 the	 inherent	 risks	 associated	with	
the	occurrence	of	medication‐	induced	osteonecrosis	 in	patients	
taking	BPs.
The	 effect	 of	 BP	 on	 implant	 outcomes	 in	 patients	 undergoing	





5.3.1 | What are the implications of the increasing 
intake of medication by the general population in 
daily practice?
Clinicians	 and	 patients	 considering	 implant	 therapy	 should	 be	
aware	 of	 possible	 medication‐	related	 implant	 failures.	 Hence,	 a	
comprehensive	 assessment	 and	 understanding	 of	 the	 patient’s	
medical	background	and	current	medications,	as	well	as	a	person‐
alized	 informed	 consent,	 should	 be	 considered	 integral	 compo‐
nents	 of	 all	 phases	 of	 contemporary	 implant	 therapy	 (initial	 and	
supportive	therapy).
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5.3.2 | What considerations should be taken in daily 
clinical practice pertaining medication intake‐ related 
implant failure?
Clinicians	 should	 consider	 the	 association	 between	 increased	 im‐
plant	failure	rate	and	the	intake	of	proton	pump	inhibitors	(PPIs)	or	
selective	 serotonin	 reuptake	 inhibitors	 (SSRIs)	 in	 their	 routine	 risk	
assessment	as	part	of	comprehensive	implant	therapy.
Clinicians	 should	 proceed	 with	 caution	 when	 implant	 therapy	
is	 considered	 in	 patients	 taking	 bisphosphonates	 (BPs)	 related	 to	
osteoporosis.
Standard	 implant	 therapy	 is	 contraindicated	 in	patients	 receiv‐
ing	high‐	dose	bisphosphonates	(BPs)	for	the	treatment	of	neoplastic	
diseases.
5.4 | Recommendations for future research
•	 To	elucidate	potential	mechanisms	of	 action	 that	would	explain	
the	effect	of	certain	medications	on	bone	and	soft	tissue	homeo‐
stasis	 around	 implants	 exhibiting	 different	 macro‐	 and	 micro‐
scopic	features	via	the	conduction	of	in vivo	preclinical	studies.
•	 To	 investigate	 potential	 cause–effect	 relationships	 between	 the	
intake	 of	 certain	 medications	 and	 implant	 outcomes	 through	
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